首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Synthesis of (11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
【24h】

Synthesis of (11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.

机译:合成(11C)Iressa作为表皮生长因子受体酪氨酸激酶的新型潜在PET癌症显像剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/micromol specific activity at end of bombardment (EOB).
机译:Iressa(吉非替尼)是一种表皮生长因子受体酪氨酸激酶(EGFR-TK)的口服活性抑制剂,参与对癌细胞增殖,凋亡,修复和血管生成至关重要的细胞信号转导过程。 [11C] Iressa最初被设计和合成为EGFR-TK的新型潜在正电子发射断层扫描(PET)癌症成像剂,放射化学产率为30-40%,轰击结束时(EOB)的比活为4.0-6.0 Ci / micromol。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号